![Linda Lebon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Linda Lebon
Algemeen Adviseur bij
OSE IMMUNOTHERAPEUTICS
Profiel
Linda Lebon is currently the Chief Regulatory Officer at OSE Immunotherapeutics SA since 2021.
Prior to this, she worked as the Chief Regulatory Officer at Bone Therapeutics SA from 2018 to 2021.
Before that, she held the position of Vice President-Regulatory Affairs at argenx SE and Director-Regulatory Affairs at iTeos Therapeutics SA. Ms. Lebon holds an MBA from École des Hautes Études Commerciales de Paris and a graduate degree from Centre Hospitalier Universitaire de Liege.
Actieve functies van Linda Lebon
| Bedrijven | Functie | Begin |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Algemeen Adviseur | 20-12-2021 |
Eerdere bekende functies van Linda Lebon
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOSENIC SA | Algemeen Adviseur | 01-09-2021 |
| ARGENX SE | Algemeen Adviseur | - |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Algemeen Adviseur | - |
Opleiding van Linda Lebon
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
41
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
École des Hautes Études Commerciales de Paris
 École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Bone Therapeutics SA
 Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops regenerative therapy products for addressing unmet medical needs in the field of bone diseases and orthopedics | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Health Technology |
Centre Hospitalier Universitaire de Liege
 Centre Hospitalier Universitaire de Liege Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
